Home » Topics » BioWorld Science

BioWorld Science
RSS

EZH2 inhibitors patented by Yangtze River Pharmaceutical, Shanghai Haiyan Pharmaceutical Technology

June 6, 2018

Nimbus Therapeutics announces new financing

June 6, 2018

Axovant licenses gene therapy for Parkinson's disease from Oxford BioMedica

June 6, 2018

Independent DMC completes last intermediate review of SCiStar study of AST-OPC1

June 6, 2018

Kyowa Hakko Kirin, Leo Pharma launch Dovobet gel new formulation for psoriasis vulgaris in Japan

June 6, 2018

FDA provides feedback for phase III program of efgartigimod in myasthenia gravis

June 6, 2018

AbbVie seeks Japanese approval for Humira in hidradenitis suppurativa

June 6, 2018

Navitor Pharmaceuticals divulges mTOR complex 1 and glucose transport inhibitors

June 6, 2018

Spyryx presents positive data for first cohort of HOPE-1 phase II trial of SPX-101

June 6, 2018

Ionis and Biogen close strategic collaboration to develop antisense drugs for neurological diseases

June 6, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 29, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 26, 2026
Researchers identify innate immune barrier against melanoma
BioWorld
Australian researchers have identified a previously overlooked population of immune cells in the skin that physically restrain melanoma growth by engulfing live...
TROP2 ADCs progress into first-line for lung, breast cancers
BioWorld
Multiple updates on TROP2-directed antibody-drug conjugates (ADCs) for lung and breast cancers highlight both progress made and opportunities for improvement for...
Cavalon Therapeutics and Northwestern patent new Cav1.3 blockers
BioWorld Science
Cavalon Therapeutics Inc. and Northwestern University have disclosed new voltage-gated calcium channel Cav1.3 blockers potentially useful for the treatment of...